Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity
BackgroundFactors leading to severe COVID-19 remain partially known. New biomarkers predicting COVID-19 severity that are also causally involved in disease pathogenesis could improve patient management and contribute to the development of innovative therapies. Autophagy, a cytosolic structure degrad...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1505752/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558631420526592 |
|---|---|
| author | Stephane Isnard Stephane Isnard Tsoarello Mabanga Tsoarello Mabanga Léna Royston Léna Royston Léna Royston Carolina A. Berini Carolina A. Berini Simeng Bu Simeng Bu Orthy Aiyana Orthy Aiyana Hansen Feng Hansen Feng Bertrand Lebouché Bertrand Lebouché Bertrand Lebouché Bertrand Lebouché Cecilia T. Costiniuk Cecilia T. Costiniuk Joseph Cox Joseph Cox Guido Kroemer Guido Kroemer Guido Kroemer Madeleine Durand Jean-Pierre Routy Jean-Pierre Routy Jean-Pierre Routy the Biobanque Québécoise de la COVID-19 (BQC-19) |
| author_facet | Stephane Isnard Stephane Isnard Tsoarello Mabanga Tsoarello Mabanga Léna Royston Léna Royston Léna Royston Carolina A. Berini Carolina A. Berini Simeng Bu Simeng Bu Orthy Aiyana Orthy Aiyana Hansen Feng Hansen Feng Bertrand Lebouché Bertrand Lebouché Bertrand Lebouché Bertrand Lebouché Cecilia T. Costiniuk Cecilia T. Costiniuk Joseph Cox Joseph Cox Guido Kroemer Guido Kroemer Guido Kroemer Madeleine Durand Jean-Pierre Routy Jean-Pierre Routy Jean-Pierre Routy the Biobanque Québécoise de la COVID-19 (BQC-19) |
| author_sort | Stephane Isnard |
| collection | DOAJ |
| description | BackgroundFactors leading to severe COVID-19 remain partially known. New biomarkers predicting COVID-19 severity that are also causally involved in disease pathogenesis could improve patient management and contribute to the development of innovative therapies. Autophagy, a cytosolic structure degradation pathway is involved in the maintenance of cellular homeostasis, degradation of intracellular pathogens and generation of energy for immune responses. Acyl-CoA binding protein (ACBP) is a key regulator of autophagy in the context of diabetes, obesity and anorexia. The objective of our work was to assess whether circulating ACBP levels are associated with COVID-19 severity, using proteomics data from the plasma of 903 COVID-19 patients.MethodsSomalogic proteomic analysis was used to detect 5000 proteins in plasma samples collected between March 2020 and August 2021 from hospitalized participants in the province of Quebec, Canada. Plasma samples from 903 COVID-19 patients collected during their admission during acute phase of COVID-19 and 295 hospitalized controls were assessed leading to 1198 interpretable proteomic profiles. Levels of anti-SARS-CoV-2 IgG were measured by ELISA and a cell-binding assay.ResultsThe median age of the participants was 59 years, 46% were female, 65% had comorbidities. Plasma ACBP levels correlated with COVID-19 severity, in association with inflammation and anti-SARS-CoV-2 antibody levels, independently of sex or the presence of comorbidities. Samples collected during the second COVID-19 wave in Quebec had higher levels of plasma ACBP than during the first wave. Plasma ACBP levels were negatively correlated with biomarkers of T and NK cell responses interferon-γ, tumor necrosis factor-α and interleukin-21, independently of age, sex, and severity.ConclusionsCirculating ACBP levels can be considered a biomarker of COVID-19 severity linked to inflammation. The contribution of extracellular ACBP to immunometabolic responses during viral infection should be further studied. |
| format | Article |
| id | doaj-art-3fb3c0413f92465182de4f38c9ba528a |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-3fb3c0413f92465182de4f38c9ba528a2025-01-06T06:59:42ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15057521505752Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severityStephane Isnard0Stephane Isnard1Tsoarello Mabanga2Tsoarello Mabanga3Léna Royston4Léna Royston5Léna Royston6Carolina A. Berini7Carolina A. Berini8Simeng Bu9Simeng Bu10Orthy Aiyana11Orthy Aiyana12Hansen Feng13Hansen Feng14Bertrand Lebouché15Bertrand Lebouché16Bertrand Lebouché17Bertrand Lebouché18Cecilia T. Costiniuk19Cecilia T. Costiniuk20Joseph Cox21Joseph Cox22Guido Kroemer23Guido Kroemer24Guido Kroemer25Madeleine Durand26Jean-Pierre Routy27Jean-Pierre Routy28Jean-Pierre Routy29the Biobanque Québécoise de la COVID-19 (BQC-19)Inflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, CanadaInflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, CanadaInflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, CanadaDivision of Infectious Diseases, Geneva University Hospitals, Geneva, SwitzerlandInflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, CanadaInflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, CanadaInflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, CanadaInflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, CanadaInflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, CanadaDepartment of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, CanadaCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaInflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, CanadaInflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, CanadaCentre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, FranceMetabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, FranceInstitut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, assistance publique des hôpitaux de Paris (AP-HP), Paris, FranceDépartement de Microbiologie, Infectiologie et Immunologie, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, QC, CanadaInflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada0Division of Hematology, McGill University Health Centre, Montreal, QC, CanadaBackgroundFactors leading to severe COVID-19 remain partially known. New biomarkers predicting COVID-19 severity that are also causally involved in disease pathogenesis could improve patient management and contribute to the development of innovative therapies. Autophagy, a cytosolic structure degradation pathway is involved in the maintenance of cellular homeostasis, degradation of intracellular pathogens and generation of energy for immune responses. Acyl-CoA binding protein (ACBP) is a key regulator of autophagy in the context of diabetes, obesity and anorexia. The objective of our work was to assess whether circulating ACBP levels are associated with COVID-19 severity, using proteomics data from the plasma of 903 COVID-19 patients.MethodsSomalogic proteomic analysis was used to detect 5000 proteins in plasma samples collected between March 2020 and August 2021 from hospitalized participants in the province of Quebec, Canada. Plasma samples from 903 COVID-19 patients collected during their admission during acute phase of COVID-19 and 295 hospitalized controls were assessed leading to 1198 interpretable proteomic profiles. Levels of anti-SARS-CoV-2 IgG were measured by ELISA and a cell-binding assay.ResultsThe median age of the participants was 59 years, 46% were female, 65% had comorbidities. Plasma ACBP levels correlated with COVID-19 severity, in association with inflammation and anti-SARS-CoV-2 antibody levels, independently of sex or the presence of comorbidities. Samples collected during the second COVID-19 wave in Quebec had higher levels of plasma ACBP than during the first wave. Plasma ACBP levels were negatively correlated with biomarkers of T and NK cell responses interferon-γ, tumor necrosis factor-α and interleukin-21, independently of age, sex, and severity.ConclusionsCirculating ACBP levels can be considered a biomarker of COVID-19 severity linked to inflammation. The contribution of extracellular ACBP to immunometabolic responses during viral infection should be further studied.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1505752/fullAcyl-CoA-binding proteinautophagyCOVID-19SARS-CoV-2proteomicsBQC-19 biobank |
| spellingShingle | Stephane Isnard Stephane Isnard Tsoarello Mabanga Tsoarello Mabanga Léna Royston Léna Royston Léna Royston Carolina A. Berini Carolina A. Berini Simeng Bu Simeng Bu Orthy Aiyana Orthy Aiyana Hansen Feng Hansen Feng Bertrand Lebouché Bertrand Lebouché Bertrand Lebouché Bertrand Lebouché Cecilia T. Costiniuk Cecilia T. Costiniuk Joseph Cox Joseph Cox Guido Kroemer Guido Kroemer Guido Kroemer Madeleine Durand Jean-Pierre Routy Jean-Pierre Routy Jean-Pierre Routy the Biobanque Québécoise de la COVID-19 (BQC-19) Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity Frontiers in Immunology Acyl-CoA-binding protein autophagy COVID-19 SARS-CoV-2 proteomics BQC-19 biobank |
| title | Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity |
| title_full | Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity |
| title_fullStr | Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity |
| title_full_unstemmed | Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity |
| title_short | Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity |
| title_sort | extracellular acyl coa binding protein as an independent biomarker of covid 19 disease severity |
| topic | Acyl-CoA-binding protein autophagy COVID-19 SARS-CoV-2 proteomics BQC-19 biobank |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1505752/full |
| work_keys_str_mv | AT stephaneisnard extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT stephaneisnard extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT tsoarellomabanga extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT tsoarellomabanga extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT lenaroyston extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT lenaroyston extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT lenaroyston extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT carolinaaberini extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT carolinaaberini extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT simengbu extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT simengbu extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT orthyaiyana extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT orthyaiyana extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT hansenfeng extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT hansenfeng extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT bertrandlebouche extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT bertrandlebouche extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT bertrandlebouche extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT bertrandlebouche extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT ceciliatcostiniuk extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT ceciliatcostiniuk extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT josephcox extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT josephcox extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT guidokroemer extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT guidokroemer extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT guidokroemer extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT madeleinedurand extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT jeanpierrerouty extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT jeanpierrerouty extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT jeanpierrerouty extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity AT thebiobanquequebecoisedelacovid19bqc19 extracellularacylcoabindingproteinasanindependentbiomarkerofcovid19diseaseseverity |